Compare Nuwellis Inc (NUWE) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs New York Times Co — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while New York Times Co trades at $66.6 (market cap $10.74B). The key difference: New York Times Co is far larger — about 4881.8× Nuwellis Inc's market cap, and New York Times Co pays a 1.38% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and New York Times Co for 81 Days on average.
| NUWE | NYT | |
|---|---|---|
Market Cap | $2.20M | $10.74B |
Volume | 121,544 | 2,096,352 |
Sector | Health | Media |
52-Week High | $146.65 | $85.86 |
52-Week Low | $0.68 | $54.66 |
Typical Hold Time | 26 Days | 81 Days |
Enterprise Value | -$1.52M | $10.14B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
The New York Times Company (NYT) trades at $64.90, up 1.3% with strong fundamentals including 12.17% net margin and consistent earnings beats. Technical indicators show bearish momentum with support at $62-64 and resistance at $65-67. Recent news highlights dividend declaration and ongoing AI copyright litigation.
Outlook remains positive with 35% analyst buy ratings and $84 consensus target, though legal risks and technical bearish signals warrant caution. Revenue growth trajectory and strong profitability support long-term value despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
